HALO logo

Halozyme Therapeutics (HALO) Accounts Payable

Annual Accounts Payable

$10.25 M
-$1.57 M-13.26%

December 31, 2024

Summary

Performance

1-Year Change

-13.26%

3-Year Change

+565.09%

5-Year Change

+59.29%

15-Year Change

+28.95%

HALO Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.91%
HALO annual accounts payable is higher than 68.91% of companies in Healthcare sector

High & Low

All-time High

$17.69 M
HALO annual accounts payable is currently -42.07% below its historical high of $17.69 million

3-Year Low

$1.54 M
HALO annual accounts payable is currently +565.09% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALObalance sheetmetrics:

Annual Accounts Receivable

$296.94 M
HALO annual accounts receivable is $296.94 million

Annual Total Liabilities

$1.70 B
HALO annual total liabilities is $1.70 billion

Annual Total Assets

$2.06 B
HALO annual total assets is $2.06 billion

Annual Current Assets

$1.09 B
HALO annual total current assets is $1.09 billion

Quarterly Accounts Payable

$10.25 M
-$2.15 M-17.33%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-46.95%

5-Year Change

-46.95%

HALO Quarterly Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

69.53%
HALO quarterly accounts payable is higher than 69.53% of companies in Healthcare sector

High & Low

All-time High

$19.32 M
HALO quarterly accounts payable is currently -46.95% below its historical high of $19.32 million

3-Year Low

$1.27 M
HALO quarterly accounts payable is currently +709.56% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALObalance sheetmetrics:

Quarterly Accounts Receivable

$296.94 M
HALO quarterly accounts receivable is $296.94 million

Quarterly Total Liabilities

$1.70 B
HALO quarterly total liabilities is $1.70 billion

Quarterly Total Assets

$2.06 B
HALO quarterly total assets is $2.06 billion

Quarterly Current Assets

$1.09 B
HALO quarterly total current assets is $1.09 billion

Accounts Payable Formula

Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers

HALO Accounts Payable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-13.3%0.0%
3 y3 years+565.1%-47.0%
5 y5 years+59.3%-47.0%

HALO Accounts Payable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-42.1%+565.1%-47.0%+709.6%
5 y5-year-42.1%+565.1%-47.0%+2267.0%
alltimeall time-42.1%+642.7%-47.0%>+9999.0%

Halozyme Therapeutics Accounts Payable History

DateAnnualQuarterly
Dec 2024
$10.25 M(-13.3%)
$10.25 M(-17.3%)
Sep 2024
-
$12.40 M(-19.7%)
Jun 2024
-
$15.43 M(+15.8%)
Mar 2024
-
$13.32 M(+12.8%)
Dec 2023
$11.82 M(-33.2%)
$11.82 M(-38.8%)
Sep 2023
-
$19.32 M(+90.9%)
Jun 2023
-
$10.12 M(+16.4%)
Mar 2023
-
$8.70 M(-50.9%)
Dec 2022
$17.69 M(+1048.2%)
$17.69 M(-2.6%)
Sep 2022
-
$18.17 M(+48.5%)
Jun 2022
-
$12.23 M(+866.2%)
Mar 2022
-
$1.27 M(-17.8%)
Dec 2021
$1.54 M(-20.1%)
$1.54 M(-53.6%)
Sep 2021
-
$3.32 M(-27.2%)
Jun 2021
-
$4.56 M(+752.9%)
Mar 2021
-
$535.00 K(-72.3%)
Dec 2020
$1.93 M(-70.0%)
$1.93 M(+345.3%)
Sep 2020
-
$433.00 K(-89.4%)
Jun 2020
-
$4.07 M(-51.1%)
Mar 2020
-
$8.32 M(+29.3%)
Dec 2019
$6.43 M(+57.7%)
$6.43 M(+49.1%)
Sep 2019
-
$4.31 M(-65.4%)
Jun 2019
-
$12.47 M(+204.9%)
Mar 2019
-
$4.09 M(+0.2%)
Dec 2018
$4.08 M(-48.7%)
$4.08 M(+22.5%)
Sep 2018
-
$3.33 M(-46.2%)
Jun 2018
-
$6.19 M(+70.5%)
Mar 2018
-
$3.63 M(-54.4%)
Dec 2017
$7.95 M(+122.1%)
$7.95 M(+91.4%)
Sep 2017
-
$4.15 M(-26.5%)
Jun 2017
-
$5.65 M(+83.5%)
Mar 2017
-
$3.08 M(-13.9%)
Dec 2016
$3.58 M(-20.5%)
$3.58 M(-22.9%)
Sep 2016
-
$4.64 M(+27.2%)
Jun 2016
-
$3.65 M(-41.2%)
Mar 2016
-
$6.21 M(+38.1%)
Dec 2015
$4.50 M(+49.8%)
$4.50 M(+1.4%)
Sep 2015
-
$4.44 M(+7.2%)
Jun 2015
-
$4.14 M(+25.4%)
Mar 2015
-
$3.30 M(+9.9%)
Dec 2014
$3.00 M
$3.00 M(-30.8%)
Sep 2014
-
$4.34 M(+11.0%)
DateAnnualQuarterly
Jun 2014
-
$3.91 M(-54.8%)
Mar 2014
-
$8.66 M(+176.2%)
Dec 2013
$3.13 M(+38.0%)
$3.13 M(-43.9%)
Sep 2013
-
$5.59 M(-25.3%)
Jun 2013
-
$7.48 M(+159.3%)
Mar 2013
-
$2.88 M(+27.0%)
Dec 2012
$2.27 M(-69.9%)
$2.27 M(-35.6%)
Sep 2012
-
$3.53 M(+69.0%)
Jun 2012
-
$2.09 M(-30.7%)
Mar 2012
-
$3.01 M(-60.2%)
Dec 2011
$7.56 M(+97.8%)
$7.56 M(+519.5%)
Sep 2011
-
$1.22 M(-29.6%)
Jun 2011
-
$1.73 M(+19.3%)
Mar 2011
-
$1.45 M(-62.0%)
Dec 2010
$3.82 M(+35.5%)
$3.82 M(+109.0%)
Sep 2010
-
$1.83 M(-13.0%)
Jun 2010
-
$2.10 M(-50.6%)
Mar 2010
-
$4.25 M(+50.7%)
Dec 2009
$2.82 M(-57.7%)
$2.82 M(-44.9%)
Sep 2009
-
$5.12 M(-5.7%)
Jun 2009
-
$5.43 M(+2.4%)
Mar 2009
-
$5.30 M(-20.5%)
Dec 2008
$6.67 M(+118.2%)
$6.67 M(+61.0%)
Sep 2008
-
$4.14 M(+47.1%)
Jun 2008
-
$2.81 M(-17.2%)
Mar 2008
-
$3.40 M(+11.2%)
Dec 2007
$3.06 M(+51.5%)
$3.06 M(+11.9%)
Sep 2007
-
$2.73 M(+76.3%)
Jun 2007
-
$1.55 M(+44.4%)
Mar 2007
-
$1.07 M(-46.9%)
Dec 2006
$2.02 M(+46.2%)
$2.02 M(+41.3%)
Sep 2006
-
$1.43 M(+29.1%)
Jun 2006
-
$1.11 M(-31.8%)
Mar 2006
-
$1.62 M(+17.5%)
Dec 2005
$1.38 M(-7.2%)
$1.38 M(-4.2%)
Sep 2005
-
$1.44 M(+1.9%)
Jun 2005
-
$1.41 M(-20.1%)
Mar 2005
-
$1.77 M(+18.9%)
Dec 2004
$1.49 M
$1.49 M(-22.7%)
Sep 2004
-
$1.92 M(+61.4%)
Jun 2004
-
$1.19 M(+87.0%)
Mar 2004
-
$637.30 K(>+9900.0%)
Mar 2002
-
$2900.00

FAQ

  • What is Halozyme Therapeutics annual accounts payable?
  • What is the all time high annual accounts payable for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual accounts payable year-on-year change?
  • What is Halozyme Therapeutics quarterly accounts payable?
  • What is the all time high quarterly accounts payable for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly accounts payable year-on-year change?

What is Halozyme Therapeutics annual accounts payable?

The current annual accounts payable of HALO is $10.25 M

What is the all time high annual accounts payable for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual accounts payable is $17.69 M

What is Halozyme Therapeutics annual accounts payable year-on-year change?

Over the past year, HALO annual accounts payable has changed by -$1.57 M (-13.26%)

What is Halozyme Therapeutics quarterly accounts payable?

The current quarterly accounts payable of HALO is $10.25 M

What is the all time high quarterly accounts payable for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly accounts payable is $19.32 M

What is Halozyme Therapeutics quarterly accounts payable year-on-year change?

Over the past year, HALO quarterly accounts payable has changed by $0.00 (0.00%)